274 related articles for article (PubMed ID: 30622147)
1. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
2. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
4. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
6. Loss of CD22 expression and expansion of a CD22
Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
Thota S; Advani A
Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
[TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar T; Szabo A; Wadleigh M; Liedtke M; Arslan S; Siebenaller C; Aldoss I; Schultz E; Hefazi M; Litzow MR; Kuo E; Wang A; Curran E; Shallis RM; Podoltsev N; Balasubramanian S; Yang J; Mattison R; Burkart M; Dinner S; Advani A; Atallah E
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):556-560.e2. PubMed ID: 32291234
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI
Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
11. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Chen J; Haughey M; Vandendries E; DeAngelo DJ; Kantarjian HM; Ruiz-Garcia A
Clin Transl Sci; 2021 Jan; 14(1):184-193. PubMed ID: 32812370
[TBL] [Abstract][Full Text] [Related]
13. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Li X; Zhou M; Qi J; Han Y
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e227-e247. PubMed ID: 33461955
[TBL] [Abstract][Full Text] [Related]
15. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
[TBL] [Abstract][Full Text] [Related]
18. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
[TBL] [Abstract][Full Text] [Related]
20. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B
Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
